Pharma firm Aurobindo Pharma today said it has received approval from Health Canada for introducing its Cefprozil tablets and Cefprozil powder for oral suspension as an antibiotic.
The company has received the approvals for its abbreviated new drug submission from Health Canada, Aurobindo Pharma said in a filing to the Bombay Stock Exchange.
Cefprozil tablets are available in strengths of 250 mg and 500 mg and Cefprozil powder for oral suspension is available in strengths of 125 mg/5ml and 250mg/5ml, the filing added.
With these approvals, Aurobindo now has 11 products approved by Health Canada, the filing added.
Health Canada is the federal department responsible for helping Canadians maintain and improve their health.
Shares of Aurobindo Pharma were trading at Rs 941.50 on the BSE, up 0.01 per cent from the previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app